Join 33,000+ subscribers getting smarter about psychedelics in under 10 minutes a week. Research 🔬, policy 🏛️, and business 📈, with a side of spicy memes. 🫠
Tap into our mycelial network.
[6-min read] Q&A with Jonathan “Quest” Brown, Integration Coach
Henry Winslowa day ago
[5-min read] Johns Hopkins experts discuss the state of psychedelic research.
Henry Winslow5 days ago
[6-min read] Q&A with Tracey Tee, Mom & Founder
Henry Winslow8 days ago
[4-min read] Drug policy foundation proposes regulatory model for psychedelics.
Henry Winslow12 days ago
[6-min read] Q&A with Shane Heath, Designer & Founder
Henry Winslow15 days ago
[5-min read] Microdosing improves mindfulness in people with ADHD.
Henry Winslow19 days ago
[6-min read] Q&A with Jesse Gould, Veteran & Founder
Henry Winslow22 days ago
[4-min read] MindMed patents antidepressant-psychedelic combination treatment.
Henry Winslowa month ago
[6-min read] Q&A with Talia Eisenberg, Serial Entrepreneur
[4-min read] California gets its third psychedelics ballot proposal.
[6-min read] Q&A with Jeannie Fontana, Founder & CEO
[5-min read] Stanford researchers study ketamine under surgical anesthesia.
[6-min read] Q&A with Nicholas Levich, Coach & Cofounder
[5-min read] FDA issues warning on off-label ketamine use.
Henry Winslow2 months ago
[5-min read] Q&A with Spencer Hawkswell, Patient Advocate & CEO
[5-min read] California governor vetoes psychedelic decrim bill.
[7-min read] Q&A with Reid Robison, Chief Clinical Officer
[5-min read] FDA accepts PharmaTher’s NDA for KETARX.
[5-min read] Q&A with Azalea Montaño-Kemp
[5-min read] Research on naturalistic psilocybin use shows lasting benefits.
[6-min read] Q&A with Kate Kincaid, Therapist & Mother
[5-min read] MAPS’ latest clinical trial paves the way for FDA approval.
[6-min read] Q&A with Raad Seraj, Angel Investor & Founder
Henry Winslow3 months ago
[5-min read] AI model accurately predicts psilocybin treatment responses.
[6-min read] Q&A with Julian Vayne, Occultist & Scholar
